1. Introduction {#s0005}
===============

Latently infected CD4 + T cells are the major barrier to HIV-1 cure efforts. The cells contain integrated proviruses that are transcriptionally silent and thus able to evade detection and clearance by the immune system. The shock-and-kill cure strategy seeks to first reactivate these latent viruses without causing global T cell activation followed by clearance of the reactivated cells by the immune system (reviewed in [@bb0175], [@bb0015]). Latency reactivating agents (LRAs) are drugs that induce HIV-1 transcription. Notable drug classes include PKC agonists and HDAC inhibitors (HDACi), which have been very effective in inducing HIV-1 transcription in cell lines ([@bb0050], [@bb0225], [@bb0115], [@bb0055]). Unfortunately, in vitro experiments with primary resting CD4 T cells from patients on suppressive antiretroviral therapy (ART) regimens suggest that most individual LRAs are unable to induce substantive amounts of HIV-1 transcription with the notable exception of PKC agonists bryostatin-1-1 ([@bb0045]) and ingenol ([@bb0190]). However, LRA combinations in the same system are capable of inducing significant HIV-1 transcription ([@bb0110], [@bb0090], [@bb0065]).

The other half of the cure strategy deals with killing newly reactivated infected CD4 + T cells. Recent experiments suggest that reactivation from latency is not enough to induce cell death ([@bb0170]), and therefore there may be a need for immune mediated eradication. Expanded CD8 + T cell lines were able to clear reactivated latently infected resting CD4 + T cells following exposure to the HDAC inhibitor, vorinostat ([@bb0195]). However primary CD8 + T cells from patients on suppressive ART regimens that were pre-stimulated with overlapping Gag peptides were unable to consistently reduce the amount of HIV-1 mRNA induced from autologous resting CD4 + T cells that were activated with PMA and ionomycin ([@bb0205]).

The combination of romidepsin and bryostatin-1 has been shown to be one of the best inducers of latent HIV-1 in primary CD4 + T cells ([@bb0110]). However, bryostatin-1 has been showed to be involved in the modulation of NFkB and NFAT ([@bb0220]) and romidepsin is known to affect the function of NK cells and CD8 + T cells ([@bb0100], [@bb0095]). Other HDAC inhibitors have furthermore been known to induce Treg cells in vitro ([@bb0005], [@bb0200]). The immunomodulatory activity of the two drug classes thought to be most promising in cure efforts therefore needs to be further studied in the context of CD8 + T cell elimination of reactivated latently infected CD4 + T cells.

In this study, we sought to determine the ability of HIV-specific CD8 + T cells from patients with progressive HIV-1 disease on ART (chronic progressors) to kill HIV-infected CD4 + T cells after treatment with LRAs. To elucidate the contribution of the drug treatments the HIV-specific response, suppression of infection was examined with elite suppressor CD8 + T cells that had been pre-treated with different LRAs, including an HDAC inhibitor, a bromodomain-containing protein 4 inhibitor, and multiple PKC agonists. Finally, we examined the mechanisms that may have contributed to the effects of drug treatment on CD8 + T cell function. Our results have implications for the HIV-1 cure agenda.

2. Methods {#s0010}
==========

2.1. Donor blood samples {#s0015}
------------------------

HIV-1 positive and HIV-1 negative blood samples were obtained from donors with written, informed consent and handled according to a Johns Hopkins University IRB approved protocol. The chronic progressors studied were HIV-1 positive individuals who were started on suppressive ART therapy during chronic infection and have a viral load of \< 20 copies of HIV RNA/mL. Elite suppressors are patients who have maintained undetectable viral loads without antiretroviral therapy. The clinical characteristics of the patients are summarized in [Table 1](#t0005){ref-type="table"}.

2.2. Primary cell isolations {#s0020}
----------------------------

PBMCs were obtained from whole blood via Ficoll-Paque PLUS gradient centrifugation (GE Healthcare Life Sciences). PBMCs underwent negative selection for CD4 + T cells using the MACS system (CD4 Isolation Kit, Miltenyi Biotech). Resting CD4 + T cells were further isolated from the bulk population by depleting CD25 +, CD69 +, and HLA-DR + cells (CD25 microbeads, CD69 Isolation Kit, and HLA-DR microbeads; Miltenyi Biotech). When applicable, CD8 + T cells were obtained via positive selection from PBMCs (CD8 microbeads, Miltenyi Biotech) prior to any negative selection performed in experiments described below.

2.3. Latency reactivation ex vivo and autologous suppression {#s0025}
------------------------------------------------------------

Resting CD4 + T cells isolated from fresh blood samples from ART-suppressed individuals as described above ("Primary Cell Isolation") were plated in 12-well plates with 5 × 10^6^ ([@bb0055]) cells per replicate in non-stimulating media (RPMI 1640 + Glutamax, 10% FBS) and treated alone for six hours with the combination of bryostatin-1 (B, 10 nM; Sigma Aldrich) and romidepsin (R, 40 nM; Selleck Chemicals) in the presence of efavirenz (EFV, 10 μM) and raltegravir (RAL, 4 μM) to prevent new infection and more closely mimic in vivo conditions. CD8 + T cells were isolated at this time as described above from PBMCs that had been previously stimulated for seven days in the presence of 100 U IL-2/mL and overlapping consensus Gag and Nef peptides (10 μg/mL; AIDS Reagent Database). At the conclusion of the six hours, the pre-stimulated CD8 + T cells were co-cultured with the resting CD4 + T cells at a 1:1 effector:target ratio and concentration of 5 × 10^6^ ([@bb0055]) cells/mL for another 18 h in the presence of B/R, EFV, and RAL at the same concentration as the initial treatment. The CD8 + T cells were not washed prior to co-culture with resting CD4 + T cells. In a second set of experiments, the CD8 + and CD4 + T cells were co-cultured together for 24 h in the presence of B/R, EFV, and RAL. For each replicate, at the conclusion of the full 24 h, supernatant samples and the full 5 × 10^6^ ([@bb0055]) cell samples were harvested and placed in TRIzol LS and TRIzol (Life Technologies), respectively, for the isolation of supernatant and cell-associated RNA.

2.4. Isolation and quantification of cell-associated and supernatant HIV-1 mRNA {#s0030}
-------------------------------------------------------------------------------

Cell-associated and supernatant RNA were isolated, and the HIV-1 mRNA present in those samples was then quantified as previously described ([@bb0045], [@bb0110], [@bb0205]). Supernatant RNA samples were measured on a Roche LightCycler 480 Real-Time PCR thermocycler with TaqMan Fast Advanced Mastermix (Applied Biosystems) run as per manufacturer\'s instructions and the following primers: Forward (5′ → 3′) CAGATGCTGCATATAAGCAGCTG (9501--9523), Reverse (5′ → 3′) TTTTTTTTTTTTTTTTTTTTTTTTGAAGCAC (9629-poly A). The probe used is as follows: (5′ → 3′) FAM-CCTGTACTGGGTCTCTCTGG-MGB (9531--9550) (all nucleotide coordinates relative to HXB2 consensus sequence). The molecular standard curves used for the quantification were generated using serial dilutions of a TOPO plasmid containing the final 352 nucleotides of the HIV-1 genomic RNA with the addition of 30 deoxyadenosines on the 5′ end to mimic the poly-A tail.

2.5. Latency reactivation agents\' effects on autologous suppression of ex vivo infection {#s0035}
-----------------------------------------------------------------------------------------

Autologous bulk CD8 + and CD4 + T cells were freshly isolated from PBMCs from elite suppressors as described above ("Primary Cell Isolation") for a modified version of a previously described HIV suppression assay ([@bb0040]). CD8 + T cells were treated for six hours in non-stimulating media (RPMI 1640 + Glutamax, 10% FBS) with either nothing, DMSO, romidepsin (40 nM), JQ1 (1 μM; Sigma Aldrich), vorinostat (335 nM), panobinostat (30 nM), bryostatin-1 at three concentrations (10 nM, 1 nM, 0.1 nM), or prostratin at two concentrations (1 μM, 0.3 μM; Sigma Aldrich) alone or in the combinations of romidepsin and bryostatin-1, romidepsin and prostratin, or bryostatin-1 and JQ1 at those concentrations. Meanwhile, the bulk CD4 + T cells were spinoculated at 1200 ×* g* for two hours at 37 °C with HIV-1~NL4 − 3\ ∆ Env − GFP~, a replication incompetent lab strain pseudovirus with *env* replaced with *gfp* and whose expression is controlled by the HIV promoter. At the conclusion of the six-hour drug treatments, the drug was washed from the CD8 + T cells before the cells were added in a 1:1 effector:target ratio to the spinoculated CD4 + T cells. The cells co-cultured in nonstimulating media (RPMI 1640 + Glutamax, 10% FBS) were incubated for three days prior to FACS analysis.

2.6. Bryostatin-1 treatment and its effects on cytokine production {#s0040}
------------------------------------------------------------------

PBMCs isolated from elite suppressors were plated at a concentration of 1 × 10^6^ ([@bb0055]) cells per mL in 48-well plates and treated for six hours with nothing, DMSO, romidepsin (40 nM), bryostatin-1 (10 nM), and the combination of romidepsin and bryostatin-1. After treatment, cells were washed and then re-plated as before in non-stimulating media (RPMI 1640 + Glutamax, 10% FBS). All samples were cultured with Golgi Plug and Golgi Stop (BD Biosciences) as per manufacturer\'s instructions and 1 μg/mL of anti-CD28 and anti-CD49d antibodies (NA/LE anti-CD28 clone CD28.2, anti-CD49d clone 9F10; BD Biosciences). The no-stimulation control had no additional treatment added, and the two stimulation conditions were incubated with 10 μg/mL overlapping consensus Gag peptides and 1 μg/mL anti-CD3 for stimulation (NA/LE anti-CD3 clone HIT3a; BD Biosciences), respectively.

2.7. General effects of latency reactivation agents on immune markers and cell death {#s0045}
------------------------------------------------------------------------------------

PBMCs isolated from HIV-negative donor blood were plated at a concentration of 1 × 10^6^ ([@bb0055]) cells per mL in 48-well plates and treated for six hours with nothing, DMSO, romidepsin (40 nM), bryostatin-1 at three concentrations (10 nM, 1 nM, 0.1 nM), prostratin (0.3 μM), and the combination of romidepsin (40 nM) and bryostatin-1 (10 nM). The doses of these drugs were selected based on the concentrations needed to reverse latency either alone or in combination ([@bb0110]). 40 nM of romidepsin is below the concentration of the plasma levels achieved in patients treated with this drug for lymphoma ([@bb0215]). Plasma bryostatin-1 levels of close to 1 nM have been achieved in patients receiving the highest tolerated dose of the drug ([@bb0180]). Two sets of cultures were set aside for analysis by FACS at six hours post-treatment and 18 hours post-treatment. For the rest of the cultures, cells were washed after six hours of drug treatment prior to replating in fresh plates at the same concentration of cells in non-stimulating media (RPMI 1640 + Glutamax, 10% FBS) either in the presence or absence of 1 μg/mL anti-CD3/CD28 antibodies (NA/LE anti-CD3 clone HIT3a, anti-CD28 clone CD28.2; BD Biosciences) for an additional 1, 2, or 3 days before FACS analysis.

2.8. FACS analysis of suppression and immune markers {#s0050}
----------------------------------------------------

For the suppression experiments, samples were analyzed for infected CD4 + T cells by staining for CD3 (PacBlue, BD Biosciences), CD4 (BV605, Biolegend), and CD8 (APC-H7, BD Biosciences) and examining for the GFP + (pseudovirus infected) cells. The amount of suppression was calculated by comparing the amount of infected CD4 + T cells with CD8 + T cell co-culture to those without effector cell co-culture (% Suppression = \[1 − (% GFP + CD4 + T cells cultured with CD8 + T cells) / (% GFP + CD4 + T cells without effectors)\] × 100%). Intracellular cytokine expression was determined with the following panel: CD3·PacBlue, CD4·BV605, CD8·APC-H7, CD69·APC (Biolegend), IL-2·PE (BD Biosciences), TNFα·PE-Cy7 (BD Biosciences), IFNγ·PerCP-Cy5.5 (BD Biosciences), and Perforin-FITC (Cell Sciences). Immune markers and cell death were examined in the HIV-negative donors\' cells via three staining panels (Panel A: CD3·APC-Cy7 \[Biolegend\], CD4·BV605, CD8·APC \[BD Biosciences\], PD-1·FITC \[Biolegend\]; Panel B: CD3·PE \[BD Biosciences\], CD4·BV605, CD8·APC-H7, CD69·APC, 7-AAD \[BD Biosciences\], Annexin V·V450 \[BD Biosciences\]; Panel C: CD3·PacBlue, CD8·APC-H7, CD69·BV605, CD160·PE \[Biolegend\], TIM-3·PE-Cy7 \[Biolegend\], 2B4·APC \[BD Biosciences\]). CD69, the exhaustion markers, and Annexin V expression are shown as raw data, but expression of CD3 is compared via MFI ratio (MFI ratio = \[MFI of marker in treatment\]/\[MFI of marker in no treatment\]). All samples were run on a BD FACSCantoII flow cytometer and analyzed in FlowJo vX.0.7.

2.9. Statistics {#s0055}
---------------

Statistical analyses performed for HIV-1 RNA ([Fig. 1](#f0005){ref-type="fig"}) were conducted using Wilcoxon matched-pair signed-rank test, the nonparametric alternative to the paired *t*-test as previously described ([@bb0205]). Descriptive statistics for other experiments are presented as means and standard deviations. Comparisons of treatment groups to the control (NT) were conducted using repeated measures ANOVA model with adjusted pair-wise comparisons to NT via Dunnett\'s correction. Strength of evidence, threshold *p*-values, will be presented as: ns (\> 0.05), \* (\< 0.05), \*\* (\< 0.01), and \*\*\* (\< 0.001). Parametric methods were used due to the failure of nonparametric to detect significance for paired data with sample size less than six. All statistics and graphics were performed with GraphPad Prism 6.

3. Results {#s0060}
==========

3.1. Ex vivo reactivation of latently infected CD4 + T Cells and CD8 + effector-mediated elimination {#s0065}
----------------------------------------------------------------------------------------------------

Resting CD4 + T cells from six ART-suppressed HIV-1 + individuals were treated with 10 nM bryostatin-1 and 40 nM romidepsin (B/R) for twenty-four hours to reactivate latent HIV-1 proviruses. A subset of samples from each of the individuals was further co-cultured with autologous CD8 + T cells that had been previously cultured for 7 days in the presence of IL-2 and overlapping consensus Gag and Nef peptides to determine whether these immune effectors cells could eliminate latently infected cells. In a prior study we demonstrated that viral release occurred as early as 6 h after resting CD4 + T cell stimulation ([@bb0205]), so the CD8 + T cells were added at 6 h to minimize their exposure to the latency reversal agents. In all six individuals, cell-associated HIV mRNA was increased by a median of 12.72-fold due to B/R treatment as compared to resting CD4 + T cells cultured in the absence of drugs (*p* \< 0.0002, [Fig. 1](#f0005){ref-type="fig"}B). However, the co-culture of B/R-treated resting CD4 + T cells with stimulated CD8 + T cells did not result in a significant decrease in the amount of HIV-1 mRNA, although three of the six individuals showed a trend towards a decrease in the amount of cell-associated HIV-1 mRNA ([Fig. 1](#f0005){ref-type="fig"}B). The effect of drugs and CD8 + T cells on the release of virus into culture supernatant was also examined. HIV-1 mRNA present in culture supernatant increased significantly from an undetectable baseline (500 copies/mL) following B/R treatment to a median of 5281.6 copies/ml (*p* \< 0.001), and there was no significant difference seen when the B/R-treated CD4 + T cells were co-cultured with CD8 + T cells ([Fig. 1](#f0005){ref-type="fig"}C). Of the six individuals, only CP25 had a decrease in both cell-associated and supernatant HIV-1 mRNA due to co-culture of B/R-treated resting CD4 + T cells with CD8 + T cells ([Fig. 1](#f0005){ref-type="fig"}C). We repeated the experiments with CD8 + T cells present at the time point 0 to ensure that the failure to eliminate reactivated CD4 + T cells was not due to early transcription and translation in the absence of the effector cells. However, there was still no significant decrease in either intracellular ([Fig. 1](#f0005){ref-type="fig"}D) or extracellular mRNA expression ([Fig. 1](#f0005){ref-type="fig"}E) when the stimulated CD4 + T cells were co-cultured with CD8 + T cells.

3.2. Elite suppressor CD8 + T cell responses after ex vivo treatment with latency reactivating agents {#s0070}
-----------------------------------------------------------------------------------------------------

To elucidate whether or not the lack of an effective response to reactivated HIV-1 from latently infected CD4 + T cells in the chronic progressors was due to host factors or the drugs themselves we studied the effects of the drugs on HIV-specific CD8 + T cell responses. Elite suppressors were used for these studies, as they are known to have qualitatively superior HIV-specific CD8 + T cell responses as compared to the average chronic progressor ([@bb0035], [@bb0125], [@bb0155], [@bb0130], [@bb0075]). CD4 + T cells from ES were infected with replication incompetent HIV-1~NL4 − 3\ ∆ Env − GFP~ pseudovirus and co-cultured with autologous CD8 + T cells that had been previously incubated with a variety of latency reversing agents (LRAs), as previously described ([@bb0040], [@bb0140]). DMSO, the vehicle for all the drugs, had no effect on the CD8 + T cell-mediated suppression as compared to no treatment ([Fig. 2](#f0010){ref-type="fig"}A--E). Romidepsin (40 nM throughout) alone and bryostatin-1 at either 10 nM or 1 nM significantly inhibited the ability of elite suppressor CD8 T cells to suppress infection as compared to untreated CD8 + T cells ([Fig. 2](#f0010){ref-type="fig"}A). The combination of romidepsin and all three concentrations of bryostatin-1 tested (10 nM and 1 nM significantly inhibited suppression as compared to untreated CD8 + T cells, and the combinations of romidepsin and bryostatin-1 at either 10 nM or 1 nM were much more inhibitory than either drug alone, with an 81.8% and 84.0% reduction in the amount of suppression seen for the combination of bryostatin at 10 nM and romidepsin from each drug alone, respectively, and 72.6% and 70.8% reduction for the combination of bryostatin at 10 nM and romidepsin from each alone.

In order to determine whether the inhibition of suppression is unique to bryostatin-1 or is a feature of PKC agonists, CD8 + T cells from elite suppressors were also treated with prostratin at either 1 μM or 0.3 μM alone or in conjunction with romidepsin. As opposed to bryostatin-1, prostratin alone at either concentration had no significant effect upon the suppressive capacity of the CD8 + T cells ([Fig. 2](#f0010){ref-type="fig"}B). The combination of prostratin at 1 μM and 0.3 μM with romidepsin significantly inhibited the suppression of infection (*p* \< 0.0001), but this inhibition was very similar to the inhibition seen by romidepsin alone ([Fig. 2](#f0010){ref-type="fig"}B).

The effect of JQ1, a bromodomain-containing protein 4 inhibitor, was also examined alone and in conjunction with bryostatin-1 or prostratin as these combinations of drugs have also been shown to be effective at reversing latency in vitro ([@bb0110]). Treatment of CD8 + T cells with JQ1 (1 μM) alone resulted in a slight, nonsignificant decrease in CD8 + T cell suppression ([Fig. 2](#f0010){ref-type="fig"}C). A significant decrease in CD8 + T cell-mediated suppression was seen when JQ1 was given in combination with bryostatin-1 at 10 nM and 1 nM (*p* \< 0.001 for both), but this was not significantly different from the inhibition seen with bryostatin-1 alone at either concentration ([Fig. 2](#f0010){ref-type="fig"}C). In contrast, the combination of prostratin and JQ-1 did not have a significant effect on the CD8 + T cell function ([Fig. 2](#f0010){ref-type="fig"}D).

In order to determine whether romidepsin\'s effect on CD8 + T cell suppressive activity was unique to this drug or a feature of all HDAC inhibitors, we compared the effects of romidepsin vorionostat and panobinostat on ES CD8 + T cell function. The concentrations used were based on concentrations that had been shown to be effective in prior studies ([@bb0020], [@bb0110]) and were similar to levels that have been achieved in vivo ([@bb0215], [@bb0150], [@bb0020], [@bb0030]). While romidepsin and panobinostat had significant inhibitory effects on ES CD8 + T cells, vorinostat did not cause significant suppression ([Fig. 2](#f0010){ref-type="fig"}E). These results are similar to results obtained with HIV-specific CD8 + T cell clones ([@bb0095]).

3.3. CD8 + T cell cytokine production after LRA treatment {#s0075}
---------------------------------------------------------

We next sought to find a mechanism for the inhibition of suppression due to bryostatin-1 treatment and first examined the ability of elite suppressor HIV-specific CD8 + T cells to produce cytokines after a 6-hour treatment with bryostatin-1 and romidepsin followed by 12-h of stimulation with either Gag peptides or anti-CD3 and CD28 monoclonal antibodies. Bryostatin-1 treatment alone tended to cause an increase in the percentage of cells that produced TNF-α, both TNF-α and IFN-γ, and IL-2 following anti-CD3/CD28 stimulation (for IL-2, *p* \< 0.05; [Fig. 3](#f0015){ref-type="fig"}B). In contrast, the B/R combination caused an increase in the percentage of cytokine-producing CD8 + T cells at baseline (IFN-γ, TNF-α, and IFN-γ and TNF-α), and following stimulation with Gag peptides (TNF-α; *p* \< 0.05) and anti-CD3/CD28 monoclonal antibodies (TNF-α, TNF-α and IFN-γ, and IL-2; for IL-2 only, *p* \< 0.05). Thus it appears that a decrease in cytokine expression was not the mechanism of suppression of CD8 + T cell antiviral activity.

3.4. PKC agonist effects upon cell death and exhaustion in T cells {#s0080}
------------------------------------------------------------------

To further elucidate the mechanisms by which the LRAs affected CD8 + T cell function, CD8 + T cells from HIV-negative donors were interrogated for the amount of cell death induced by drug treatment as determined by Annexin V expression. For both 6-hour and 18-hour treatments with LRAs, the combination B/R treatment induced a trend towards a higher amount of cell death than cells treated with DMSO (not shown). To examine the effects of the LRAs on cell viability over time, cells were treated for six hours before being washed and cultured for an additional three days in the absence of stimulation. For this time course, 10 nM bryostatin-1-treated CD8 + T cells had a trend towards more cell death on day 1 and significantly more on day 2 (*p* \< 0.05). A trend towards higher cell death was likewise observed in B/*R*-treated CD8 + T cells ([Fig. 4](#f0020){ref-type="fig"}B). To model the effect of the LRAs on activated CD8 + T cells, CD8 + T cells treated with 10 nM bryostatin-1 and B/R for six hours were stimulated with anti-CD3/CD28 antibodies for an additional two days. Cells treated with anti-CD3/CD28 generally had increased cell death compared to CD8 + T cells that did not receive this treatment, but only bryostatin-1 and B/R treatment of anti-CD3 activated cells caused a significant increase in cell death compared to antibody treatment alone as determined by annexin V expression (Day 1, bryostatin-1: *p* \< 0.05; Day 2, B/R: *p* \< 0.05; [Fig. 4](#f0020){ref-type="fig"}B) and supported by trends with annexin V and 7-AAD co-expression.

We also examined the expression of the exhaustion markers PD-1, Tim-3, 2B4, and CD160 following 6 h of treatment with the different drugs as a potential cause of the observed inhibition of CD8 + T cell responses. Bryostatin-1 at 10 nM and B/R induced modest but significant increases in PD-1, TIM-3 and 2B4 expression at different time points over a 3 day time period (example of PD-1 gating shown in [Supplementary Fig. 1](#ec0005){ref-type="supplementary-material"}A; [Fig. 5](#f0025){ref-type="fig"}A--C). In order to determine the effects of the LRAs on activated cells, we looked at the expression of these exhaustion markers on cells that were exposed to drugs for 6 h and then stimulated with CD3 and CD28 specific antibodies. PD-1, CD160 and 2B4 expression levels were significantly increased in activated cells that were treated with bryostatin-1 or B/R on day 2 whereas romidepsin tended to increase CD160 expression on the activated cells at the same time point ([Fig. 6](#f0030){ref-type="fig"}A--C). Furthermore, bryostatin-1 also significantly PD-1 expression in the stimulated cells on day 2 as measured by ratio of the mean fluorescence intensity of the treated cells to that of the untreated cells (*p* \< 0.05; [Supplementary Fig. 1](#ec0005){ref-type="supplementary-material"}B).

In order to determine whether the expression of the exhaustion markers was just a marker of T cell activation we looked at CD69 expression on CD8 + T cells treated with LRAs. Bryostatin-1 treatment has been shown to induce CD69 on resting CD4 + T cells ([@bb0110]), and we found very high levels of this early activation marker on CD8 + T cells that were treated with 10 nM and 1 nM bryostatin-1, B/R, and prostratin ([Fig. 7](#f0035){ref-type="fig"}). PD-1, 2B4 and TIM-3 expression was not upregulated on prostratin-treated cells, implying that the expression of these exhaustion markers was not just a reflection of partial activation although further experiments are needed to verify this.

3.5. PKC agonist-induced modulation of TCR-related markers {#s0085}
----------------------------------------------------------

PKC agonists such as PMA have been known to downregulate CD3 ([@bb0160]), which has the potential to inhibit T cell responses. In order to determine whether LRA treatment had an effect on CD3 expression, we examined the change in the mean fluorescence intensity (MFI) of this marker. CD8 + T cells treated with bryostatin-1 at 10 nM and 1 nM and B/R had a significant decrease in CD3 expression after six hours of treatment (bryostatin-1: *p* \< 0.01 at 10 nM, *p* \< 0.05 at 1 nM; B/R: *p* \< 0.01; [Fig. 8](#f0040){ref-type="fig"}A). However, after 18 h of treatment, bryostatin-1 at 10 nM and 1 nM, the B/R combination, and prostratin alone cause significant decreases in CD3 expression compared to untreated cells (*p* \< 0.0001 for 10 nM bryostatin-1 and B/R; *p* \< 0.001 for bryostatin-1 at 1 nM and prostratin; [Fig. 8](#f0040){ref-type="fig"}A). For CD8 + T cells treated for six hours and then cultured for a day in the absence of treatment, bryostatin-1 at 10 nM and 1 nM as well as B/R continued to cause a significant decrease in CD3 expression (bryostatin-1: *p* \< 0.01, *p* \< 0.05, respectively; B/R: *p* \< 0.001; [Fig. 8](#f0040){ref-type="fig"}B). Unlike bryostatin-1 treatment alone, however, the effect of B/R on CD3 expression maintained at day 1 ([Fig. 8](#f0040){ref-type="fig"}A,B). Overall, while bryostatin-1 has an effect on CD3 expression alone, the combination of bryostatin-1 with romidepsin causes both a more severe and longer-lasting phenotype.

4. Discussion {#s0090}
=============

Current HIV-1 cure strategies seek to eliminate the latent reservoir by specifically activating HIV-1 so the immune system can clear the latently infected cells. The most promising latency reactivating agent (LRA) regimens in vitro thus far appear to be combinations of HDAC inhibitors (HDACi) and PKC agonists ([@bb0110]). However, some of these drugs have previously been suggested to have immunomodulatory effects ([@bb0095]; reviewed in [@bb0010], and [@bb0145]). In this study, we confirm that the combination of bryostatin-1 and romidepsin is effective in reversing latency, however we found that even following stimulation with high concentrations of IL-2 and Gag and Nef consensus peptides, CD8 + T cells from fully suppressed chronic progressors were unable to reduce the amount of HIV-1 mRNA associated with CD4 + T cells or prevent release of virions from these cells in the context of bryostatin-1 and romidepsin treatment. One limitation of our study is that we did not measure actual viral protein production or antigen presentation following latency reversal. It is possible that some of the mRNA we measured is defective and did not lead to the synthesis of functional proteins that could be recognized by CD8 + T cells. Another possibility is that the effects of the LRAs may be short lived in vivo since HIV-specific CD8 + T cells from patients treated with vorinostat ([@bb0195]) and romidepsin ([@bb0185]) appeared to be functional in ex vivo studies, but even a short term effect could be important for viral clearance. Another limitation is the relatively small number of patients studied in this manuscript.

In a prior study, autologous ex vivo expanded virus-specific cytototoxic T lymphocytes, but not unexpanded CD8 + T cells, from HIV infected patients were able to significantly reduce the number of latently infected cells following reversal with vorinostat ([@bb0195]). The discrepancy between that study and our findings could potentially be explained by the fact that vorinostat has much less of an effect of on CD8 + T cells than did romidepsin, bryostatin-1 and the combination of the 2 drugs. Chronic progressors\' primary CD8 + T cells are generally not effective in controlling HIV-1 replication (reviewed in [@bb0120]), which may also partially account for observed results. In order to determine other potential causes, we examined the effect of four separate LRAs alone and in combination on the HIV-specific CD8 + T cell response of elite suppressors.

Elite suppressors are HIV-positive individuals who have viral loads of \< 50 copies of HIV-1 RNA per milliliter in the absence of antiretroviral therapy ([@bb0135]). These individuals are known to have qualitatively superior HIV-specific CD8 + T cell responses than chronic progressors ([@bb0035], [@bb0125], [@bb0155], [@bb0130], [@bb0075]). We performed suppression assays with cells from four elite suppressors and found that untreated CD8 + T cells were able to suppress infection effectively but that treatment with romidepsin (40 nM) or bryostatin-1 (10 nM) alone significantly inhibited this suppression by nearly 50%. The combination of the two LRAs at those concentrations fully ablated the suppression in two individuals and otherwise significantly reduced the average suppression by 90% suggesting that the two drugs may have an additive, negative effect ([Fig. 2](#f0010){ref-type="fig"}A). Interestingly, prostratin, another PKC agonist did not have an inhibitory effect on CD8 + T cell mediated suppression, suggesting that the effect on CD8 + T cell function may not be a feature of the entire class of drugs. HDAC inhibitors such as romidepsin and panobinostat have been shown to selectively cause the death of activated cells ([@bb0095]), and PKC agonists such as bryostatin-1, prostratin, and PMA are known to cause partial activation in T cells ([@bb0080], [@bb0060], [@bb0165]), with bryostatin-1 specifically acting as a TLR-4 ligand ([@bb0025]). We therefore combined romidepsin with prostratin, which also induced partial activation as determined by CD69 expression, to determine if the additive negative effect seen when bryostatin-1 and romidepsin were combined was a general effect of adding an HDAC inhibitor to a PKC agonist. Interestingly, the combination had an equal amount of suppression as romidepsin alone ([Fig. 2](#f0010){ref-type="fig"}B). JQ1 (1 μM), a bromodomain-containing protein 4 inhibitor, also had minimal effect on CD8 + T cell mediated suppression and did not appear to have an additive inhibitory effect when it was combined with bryostatin-1. The combination of prostratin and JQ1 has also recently shown to be effective ([@bb0110]) and these drugs together did not have an adverse effect on CD8 + T cell function.

In order to determine the mechanism for the inhibition of suppression seen with romidepsin, bryostatin-1, and the combination of the two, we examined the LRA treatment-dependent toxicity and induction of exhaustion on CD8 + T cells. Bryostatin-1 treatment at 10 nM causes an increase in cell death and PD-1 expression, and combined bryostatin-1 and romidepsin treatment more closely mimics the effects of bryostatin-1 treatment as compared to romidepsin treatment, suggesting that the phenomena are bryostatin-1-mediated. The increased cell death and exhaustion shortly after treatment with 10 nM bryostatin-1 likely contributes to the CD8 + T cell dysfunction in the suppression assays, given that CD8 + T cell killing of HIV-1 infected CD4 + T cells can occur within an hour ([@bb0130]).

PKC agonists are known to downregulate CD3 ([@bb0160]) as well as CD4 ([@bb0070], [@bb0105], [@bb0085], [@bb0210]). Downregulation of CD3-TCR complexes as well as the coreceptors CD4 and CD8 may inhibit the ability of effector T cells to respond to their cognate antigen, leading us to examine the expression of these markers in T cells. We found that bryostatin-1 treatment caused transient downregulation of CD3 in unstimulated CD8 + T cells, but treatment with bryostatin-1 and romidepsin prolonged this effect. Even a transient effect may be important because we have previously shown that virion release from latently infected CD4 + T cells may occur as early as 6 h after activation ([@bb0205]), and therefore a quick immune response will be needed to eliminate reactivated CD4 + T cells.

In summary, we have shown that the HDACi/PKC agonist LRA combination of bryostatin-1 and romidepsin causes marked inhibition of the HIV-specific CD8 + T cell response, as do both drugs alone. The inhibition of the T cell response by bryostatin-1 may be due an increase in T cell death and exhaustion marker expression as well as a downregulation of CD3, resulting in a decreased ability of T cells to respond to stimuli. The combination of romidepsin with bryostatin-1 furthermore causes a more severe and possibly longer-lasting downregulation phenotype, potentially contributing to the more severe inhibition of the T cell response. Any HIV-1 cure strategy involving LRA-based reactivation will likely depend upon the immune response to eliminate any latently infected cells, but given the range of negative effects the LRAs have upon the immune response alone and in combination, each potential LRA therapy should be examined for its broad effects on adaptive immunity before use in the context of HIV-1 cure. Combinations of latency reversal agents such as prostratin and JQ1 that together do not have significant effects on HIV-specific immune responses may be the most effective candidates for the shock and kill approach to HIV-1 eradication.

The following is the supplementary data related to this article.Supplementary Fig. 1Bulk CD8 + T cell expression of PD-1 is upregulated as measured by mean fluorescence intensity (MFI). Eight HIV-negative donor PBMCs were treated with LRAs for six hours prior to washing and further culture in the presence of anti-CD3/CD28 antibodies. A) Gating schematic for PD-1 as measured in [Fig. 5](#f0025){ref-type="fig"}, [Fig. 6](#f0030){ref-type="fig"}. B) Expression of PD-1 as calculated instead by the MFI of PD-1 in treated cells divided by the MFI of PD-1 in untreated cells. \* *p* \< 0.05.Supplementary Fig. 1
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![Nef- and Gag-stimulated CD8 + T cells from chronic progressors are not capable of eliminating newly-reactivated autologous CD4 + T cells following bryostatin-1/romidepsin-treatment. A) Schematic of methods. Blue arrows indicate methods common to both experiments, red arrows indicate methods for [Fig. 1](#f0005){ref-type="fig"}B and C, and green arrows indicate methods for [Fig. 1](#f0005){ref-type="fig"}D and E. B) Level of cell-associated HIV-1 mRNA seen with no stimulation (NS), treatment with bryostatin-1/romidepsin (B/R) or treatment with B/R and co-culture with CD8 + T cells for 18 h. No significance is indicated by n.s., and the listed *p*-value indicates the level of significance as determined by a Wilcoxon signed rank test for significance. C) Level of HIV-1 mRNA present in culture supernatant for 6-hour drug treatment followed by 18-hour CD8 + T cell co-culture. Dotted line indicates the level of detection (500 copies HIV mRNA/mL). The listed *p*-value indicates the level of significance as determined by a Wilcoxon signed rank test for significance. D) Cell-associated HIV mRNA from 24-hour drug treatment and CD8 + T cell co-culture with resting CD4 + T cells. The listed *p*-value indicates the level of significance as determined by a Wilcoxon signed rank test for significance. E) Supernatant HIV mRNA from 24-hour drug treatment and CD8 + T cell co-culture with resting CD4 + T cells. The listed *p*-value indicates the level of significance as determined by a Wilcoxon signed rank test for significance. Dotted line indicates the level of detection (100 copies HIV mRNA/mL). Mean ± standard error of 1--3 replicates is shown for each individual.](gr1){#f0005}

![Elite suppressor CD8 + T cell responses are inhibited by bryostatin-1 and romidepsin alone and in combination. CD8 + T cells from 4 elite suppressors were preincubated with the indicated LRAs for six hours prior to the addition to autologous CD4 + T cells infected with lab strain HIV-1 pseudovirus in a 1:1 effector:target ratio and the percent suppression of viral replication was determined. Triplicates were performed and the mean values are shown for each individual. For panels D and E, data from 2 separate experiments with cells from ES6, ES22, and ES24 were averaged, and data from an additional elite suppressor was included. A) Comparison of bryostatin-1 and romidepsin treatments. B) Comparison of prostratin and romidepsin treatments. C) Comparison of bryostatin-1 and JQ1 treatments. D) Comparison of prostratin and JQ1 treatment. E) Comparison of romidepsin and other HDAC inhibitors. One-way repeated measures ANOVAs were used to determine significance for each of the two sets of experiments. Symbols directly above treatments indicate differences from NT, no treatment. \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001, \*\*\*\* *p* \< 0.0001.](gr2){#f0010}

![Production of IFN-γ, TNF-α, and IL-2 by CD8 + T cells increases with bryostatin-1 treatment. IFN-γ (A), TNF-α (B), simultaneous IFN-γ and TNF-α (C), and IL-2 (D) production in unstimulated (NS), Gag-peptide stimulated, and anti-CD3/CD28 stimulated CD8 + T cells is shown for each of three elite suppressors with the mean ± standard error. Significance was determined via a series of one-way repeated measures ANOVAs examining each of the twelve conditions separately, and level of significance indicated above a bar is in comparison to no treatment from the same stimulation. \* *p* \< 0.05.](gr3){#f0015}

![Bryostatin-1 and bryostatin-1/romidepsin combination treatments cause an increase in CD8 + T cell death. Eight HIV negative donors\' PBMCs were treated with LRAs and examined for annexin V expression on CD8 + T cells. A) Annexin V expression in CD8 + T cells treated with drug for 6 h and then cultured for three days post-treatment in non-stimulating media. B) Annexin V expression in CD8 + T cells treated with drug for 6 h and then stimulated with anti-CD3/CD28 for either one or two days afterward. C) Annexin V and 7-AAD expression in CD8 + T cells treated with drug for 6 h and then stimulated with anti-CD3/CD28 for either one or two days afterward. One-way repeated measures ANOVAs were used to calculate significance, and the level of significance indicated is in comparison to the no treatment condition. \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001, \*\*\*\* *p* \< 0.0001.](gr4){#f0020}

![Bryostatin-1 treatment induces an increase in exhaustion marker expression in unstimulated CD8 + T cells. Eight HIV-negative donors\' PBMCs were treated with LRAs and examined for PD-1 expression on CD8 + T cells, and four donors\' PBMCs were examined for TIM-3, 2B4, and CD160 expression. A) PD-1 expression in CD8 + T cells treated with drug for 6 h and then incubated in non-stimulating media for an additional three days. B) TIM-3 expression. C) 2B4 expression. D) CD160 expression. The level of significance indicated is in comparison to no treatment. \* *p* \< 0.05, \*\* *p* \< 0.01.](gr5){#f0025}

![Bryostatin-1 treatment induces an increase in exhaustion marker expression in stimulated CD8 + T cells. Eight HIV-negative donors\' PBMCs were treated with LRAs and examined for PD-1 expression on CD8 + T cells, and four donors\' PBMCs were examined for TIM-3, 2B4, and CD160 expression. A) PD-1 expression in CD8 + T cells treated with drug for 6 h and then incubated with anti-CD3/CD28 antibodies for an additional two days. B) 2B4 expression. C) CD160 expression. D) TIM-3 expression. The level of significance indicated is in comparison to no treatment. \* *p* \< 0.05, \*\* *p* \< 0.01.](gr6){#f0030}

![CD69 expression is upregulated due to treatment with PKC agonists. Eight HIV-negative donors\' PBMCs were treated with LRAs for 6 h before being washed and then cultured in non-stimulating media for up to three days and examined for CD69 expression on CD8 + T cells. Mean expression ± standard error is indicated for each treatment. Bryostatin-1 treatment at 10 nM and 1 nM and bryostatin-1 (10 nM)/romidepsin treatment all significantly upregulate CD69 for all four timepoints (*p* \< 0.0001), as did prostratin treatment (*p* \< 0.001, *p* \< 0.001, *p* \< 0.01, and *p* \< 0.05 at the respective timepoints) as calculated by multiple one-way repeated measures ANOVAs.](gr7){#f0035}

![CD3 expression is decreased due to treatment with bryostatin-1, prostratin, and the combination of bryostatin-1/romidepsin. Eight HIV-negative donors\' PBMCs were treated with LRAs for at least 6 h and examined for CD3 expression on CD8 + T cells. A) Mean fluorescence intensity (MFI) of CD3 expression in CD8 + T cells treated with drug for 6 or 18 h normalized to no treatment. One-way repeated measures ANOVAs were used to calculate significance for 6-hour and 18-hour treatments separately. B) Mean fluorescence intensity (MFI) of CD3 expression in CD8 + T cells treated with drug for 6 h and then incubated in non-stimulating media for one day afterward normalized to no treatment. A one-way repeated measures ANOVA was used to calculate significance. The level of significance indicated is in comparison to vehicle (DMSO). \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001, \*\*\*\* *p* \< 0.0001.](gr8){#f0040}

###### 

Clinical characteristics of the chronic progressors studied.

Table 1.

  Subject   Current CD4 + T cell count   Nadir CD4 + T cell count   Time on suppressive regimen   Current regiment   HLA-A    HLA-B
  --------- ---------------------------- -------------------------- ----------------------------- ------------------ -------- --------
  CP8       424                          18                         8 years                       3TC, RAL EFV       1, 68    57, 58
  CP9       991                          190                        8 years                       TDF, FTC, DRV/c    34, 68   58, 81
  CP11      1032                         177                        8 years                       TDF, FTC, DRV/r    2, 11    25, 57
  CP 14     646                          12                         4 years                       DRV/r, DTG                  
  CP 16     921                          203                        5 years                       3TC, ABC, DTG      29, 20   42, 81
  CP25      584                          NA                         4 years                       TDF, FTC, RAL      3, 30    8, 42
  ES 3      1149                         NA                         NA                            NA                 25, 68   51, 57
  ES 6      601                          NA                         NA                            NA                 23       15, 57
  ES 9      798                          NA                         NA                            NA                 2, 30    27, 57
  ES 22     1033                         NA                         NA                            NA                 30, 31   15, 57
  ES 24     1742                         NA                         NA                            NA                 24, 30   7, 57
  ES 31     1236                         NA                         NA                            NA                 3        27, 58

3TC: lamivudine, ABC: abacavir, FTC: emtricitabine, TDF: tenofovir, DTG: dolutegravir, EFV: efavirenz, RAL: raltegravir, DRV/c: cobicistat boosted darunavir, DRV/r: ritonavir boosted darunavir.

NA: Not applicable.
